DataMeds AI, Inc. (WGRX) Form 8-K — Oct 16, 2026
DataMeds AI entered an exclusive IP license with REBOOT Health AI on October 13, 2026, licensing the REBOOT Health AI Platform as the reconfigured 'DataMeds Platform' for managing GLP-1 users in its direct-to-consumer weight management business. As consideration, DataMeds issued REBOOT 666,667 shares valued at $2,000,000, with a true-up mechanism requiring additional shares if the market value falls below $2 million after 180 days, plus a $50,000 payment and an ongoing revenue share on Adjusted Gross Revenue. The same filing updates the Nasdaq listing deficiency disclosed in April 2026, when stockholders' equity of negative $12.4 million fell below the $2.5 million minimum.
Key figures
- Shares Offered
- 666667
- Debt extinguished
- $18.7 million
- Payment to reboot
- $50,000
- Ip license share value
- $2,000,000
- Shares issued to axe computer
- 636328
- Estimated reconfiguration cost
- $100,000 minimum
- Shortfall trueup deadline days
- 180
- Vendor payables converted to equity
- $1.5 million
- Prior stockholders equity deficiency
- $(12,447,801)
- Minimum stockholders equity requirement
- $2,500,000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.